[ad_1]
Joon-wook Kwon, deputy director of the Central Defense Response Headquarters, is holding regular briefings. Yonhap news provided
The multinational pharmaceutical company Pfizer announced that 90% of the vaccine has been confirmed to prevent new coronavirus infections (COVID-19, Corona 19), while the government prepares to introduce a corona 19 vaccine in the second half of next year. .
At a briefing held at the Osong Center for Disease Control and Prevention in North Chungcheong Province on 10 this month, Kwon Jun-wook, head of the second vice president of Defense Countermeasures Headquarters, said: “We obtained vaccines through international organizations, we saw side effects in leading countries and we meticulously reviewed vaccination strategies with experts · The complementary low-temperature distribution system (cold chain) must be taken care of and several systems must be completed.” He added: “I think we need to make practical preparations with the goal of continuing once time is secured after the second quarter. I’m doing.”
According to Bang Dae-bon, the supply and demand for the national Corona 19 vaccine comes in two ways. The first is to secure 20% of vaccine needs by 2021 through KOVAX, an international vaccine joint procurement project. On the 9th of last month, Korea sent a confirmation letter to Kovacs and completed the advance payment. This includes a vaccine that Pfizer is recently developing. Consultation with individual pharmaceutical companies is also under way. Deputy CEO Kwon said: “We now have a promise to keep each other confidential about the general content of each global pharmaceutical company.”
The Pfizer vaccine must be distributed at low temperatures below -70 ° C using messenger RNA (mRNA). Assistant Director General Kwon said: “As we face the flu vaccine situation this time, we are more aware of the importance of the cold distribution system and the cold chain.” I would like to say that we are reviewing and discussing it. ” He added: “I wonder if a fairly complex preparation process, a sophisticated simulation and even repeated training sessions are required.”
Regarding the timing of the approval of the Pfizer vaccine, Kwon said: “In the case of Pfizer, the clinical trial has not finished and the US Food and Drug Administration (FDA) announced the criteria for evaluating the trial. clinical course of the COVID-19 vaccine. He said he would watch it for up to two months. “It’s probably going through a two-month period already, but I think the vaccine will be approved in December.
It is estimated that the number of vaccines that are started during the year will increase worldwide. Assistant CEO Kwon said, “In addition to Pfizer, other companies will announce clinical trials, respectively,” he said. “If that happens, some countries around the world are determined that vaccination will not start this year.”
[ad_2]
